FutureCeuticals Announces Publication of Groundbreaking Study on CognatiQ®'s Same-Day Cognitive Benefits

October 11, 2024 01:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

MOMENCE, Ill., Oct. 10, 2024 /PRNewswire/ -- FutureCeuticals proudly announces the publication of another new scientific article, once again validating the cognitive performance benefits of its patented ingredient, CognatiQ®. The results of the study, conducted at Auburn University and published in the journal Nutrients, demonstrate CognatiQ's benefits for cognitive performance in a large, diverse and healthy group of subjects.

The study is the very first of its kind to challenge the effectiveness of a cognitive performance ingredient in an at-home setting intended to mimic actual, real-life conditions rather than the highly controlled laboratory settings traditionally used by researchers.

The paper reports that a single, 200mg serving of CognatiQ significantly improved cognitive performance just one hour post-ingestion, directly impacting "working memory," considered among the most important elements of memory and reported to be crucial for reasoning, comprehension and decision-making. Tested measures showed drastic improvements from a single dose, ranging from 25% to as much as 80% improvement. Targeted benefits described in the paper included focus, accuracy and concentration, achieved while helping to alleviate the impacts of mental fatigue.

"Working memory" is a well-known term for neurologists and neuroscientists, but the term has recently experienced a resurgence in the public discourse, thanks in part to New York Times best-selling author, Dr. Richard Restak, world-renowned neurologist. The New York Times recently published a book review reporting Dr. Restak's conclusion that working memory "is the most critical type of memory," particularly as we age.

"We are pleased the world is finally beginning to realize what neurologists have known for a long time: working memory is among the most crucial parts of our brain function," shared J. Randal Wexler, who leads FutureCeuticals' R&D Department.

"The findings reported in this most recent paper directly link a single dose of CognatiQ to very significant improvements in working memory. We believe these findings demonstrate that CognatiQ can provide large, noticeable changes in cognitive performance, quickly," declared Mr. Wexler.

Visit futureceuticals.com/cognatiq to learn more.

About FutureCeuticals

FutureCeuticals is a family-owned leader in the research, development and manufacture of fruit, vegetable, and grain-based powders and extracts for the functional food, beverage and dietary supplement markets. We unlock the synergistic power of plants through the discovery and research of innovative and nutritious plant-based ingredients. CognatiQ® is available exclusively from FutureCeuticals.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.